Broad Institute

JUNE 14, 2023

She is also director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and provost for medical affairs of Cornell University. Glimcher, M.D.,

Medical Schools 52

Medical Schools Immune Response Science Hospitals 52

Broad Institute

AUGUST 7, 2023

Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard Medical School (HMS) researchers has discovered how STING activates those two pathways. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.

Regulations 91

Regulations Clinical Trials Engineering Science 91

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. MONDAY, Jan. SOURCES: Patrick A.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

PLOS: DNA Science

SEPTEMBER 5, 2024

Researchers from Harvard Medical School describe a new ChatGPT-like model that can guide clinical decision-making to diagnose, treat, and predict survival for several types of cancer. This removes the cancer’s blocking of the immune response, so that T cells can fight the cancer. Their report appears in Nature.

Treatment 71

Treatment FDA Approval DNA Small Molecule 71

The Pharma Data

APRIL 22, 2023

Multiple sclerosis (MS) is a devastating autoimmune disease that destroys the protective myelin covering around nerves, disrupting communication between the brain and body, and causing patients’ ability to move and function to progressively decline. million individuals that currently have to live with the disease.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

The Pharma Data

JANUARY 3, 2021

The clinical study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), Santa Casa de Misericórdia de Santos Hospital (Santos, Brazil) and INTRIALS, a world-class, full-service Latin American CRO based in São Paulo, Brazil. . NEW YORK and LONDON, Jan. NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

DrugBank

FEBRUARY 12, 2025

CMap utilizes gene expression profiles to connect drugs, genes, and diseases, enabling researchers to identify potential repurposing candidates based on their transcriptional signatures. They discovered that cimetidine inhibits gene expression in tumor growth and metastasis, suggesting that it could effectively slow disease progression. 

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

The Pharma Data

NOVEMBER 1, 2020

Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug. Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. Clinical Data Expected by End of Year. NEW YORK and LONDON, Nov.

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

Broad Institute

NOVEMBER 20, 2024

The intestine maintains a delicate balance in the body, absorbing nutrients and water while maintaining a healthy relationship with the gut microbiome, but this equilibrium is disrupted in parts of the intestine in conditions such as celiac disease, ulcerative colitis, and Crohn’s disease.

Regulations 84

Regulations Immune Response Molecular Biology Disease 84

Broad Institute

NOVEMBER 6, 2024

By Leah Eisenstadt November 6, 2024 Credit: Ricardo Job-Reese, Broad Communications Despite being one of the rarer complications from immune checkpoint inhibitors, myocarditis is the most deadly. This study is a game-changer, paving the way to unearthing the roots of these complications.

Immune Response 125

Immune Response Medical Schools Clinical Trials Treatment 125

Broad Institute

NOVEMBER 6, 2024

We don’t have good therapeutic solutions and we often have to stop the antitumor therapy or give large amounts of steroids that will also shut down the very immune response that’s fighting the cancer. Patients can even develop life-threatening organ inflammation after a single dose. How did you go about launching this effort?

Research 131

Research Immune Response Hospitals Therapies 131

The Pharma Data

DECEMBER 29, 2020

The vaccine — which right now is known as NVX-CoV2373 — comes in two doses and is designed to enhance the body’s immune response to the coronavirus’ distinctive spike protein. National Institute of Allergy and Infectious Diseases, said last week. “They know someone who had a severe case or died. .

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52